Update on tubulin-binding agents

Gerhardt Attard; Alastair Greystoke; Stan Kaye; Johann De Bono

doi:10.1016/j.patbio.2005.03.003

Update on tubulin-binding agents

Gerhardt Attard, Alastair Greystoke, Stan Kaye, Johann De Bono

Research output: Contribution to journal › Article › peer-review

Abstract

The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and discover new compounds that target the microtubule. These strategies are all aimed at improving on (1) anti-tumour activity, (2) toxicity profile and (3) pharmacology. Drugs undergoing clinical development include the novel semi-synthetic taxane derivatives (DJ-927, XRP6258 and XRP9881), the epothilones, the dolastations, vinflunine and the combretastatin analogues. In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established. © 2005 Elsevier SAS. All rights reserved.

Original language	English
Pages (from-to)	72-84
Number of pages	12
Journal	Pathologie Biologie
Volume	54
Issue number	2
DOIs	https://doi.org/10.1016/j.patbio.2005.03.003
Publication status	Published - Mar 2006

Keywords

Combretastatin analogues
Dolastations
Taxanes
Tubulin-binding
Vinca alkaloids
Vinflunine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.patbio.2005.03.003

Cite this

@article{ce9aca117b6f44269b529000675cc86f,

title = "Update on tubulin-binding agents",

abstract = "The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and discover new compounds that target the microtubule. These strategies are all aimed at improving on (1) anti-tumour activity, (2) toxicity profile and (3) pharmacology. Drugs undergoing clinical development include the novel semi-synthetic taxane derivatives (DJ-927, XRP6258 and XRP9881), the epothilones, the dolastations, vinflunine and the combretastatin analogues. In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established. {\textcopyright} 2005 Elsevier SAS. All rights reserved.",

keywords = "Combretastatin analogues, Dolastations, Taxanes, Tubulin-binding, Vinca alkaloids, Vinflunine",

author = "Gerhardt Attard and Alastair Greystoke and Stan Kaye and {De Bono}, Johann",

year = "2006",

month = mar,

doi = "10.1016/j.patbio.2005.03.003",

language = "English",

volume = "54",

pages = "72--84",

journal = "Pathologie Biologie",

issn = "0369-8114",

publisher = "Elsevier Masson s.r.l.",

number = "2",

}

TY - JOUR

T1 - Update on tubulin-binding agents

AU - Attard, Gerhardt

AU - Greystoke, Alastair

AU - Kaye, Stan

AU - De Bono, Johann

PY - 2006/3

Y1 - 2006/3

N2 - The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and discover new compounds that target the microtubule. These strategies are all aimed at improving on (1) anti-tumour activity, (2) toxicity profile and (3) pharmacology. Drugs undergoing clinical development include the novel semi-synthetic taxane derivatives (DJ-927, XRP6258 and XRP9881), the epothilones, the dolastations, vinflunine and the combretastatin analogues. In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established. © 2005 Elsevier SAS. All rights reserved.

AB - The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and discover new compounds that target the microtubule. These strategies are all aimed at improving on (1) anti-tumour activity, (2) toxicity profile and (3) pharmacology. Drugs undergoing clinical development include the novel semi-synthetic taxane derivatives (DJ-927, XRP6258 and XRP9881), the epothilones, the dolastations, vinflunine and the combretastatin analogues. In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established. © 2005 Elsevier SAS. All rights reserved.

KW - Combretastatin analogues

KW - Dolastations

KW - Taxanes

KW - Tubulin-binding

KW - Vinca alkaloids

KW - Vinflunine

U2 - 10.1016/j.patbio.2005.03.003

DO - 10.1016/j.patbio.2005.03.003

M3 - Article

C2 - 16545633

SN - 0369-8114

VL - 54

SP - 72

EP - 84

JO - Pathologie Biologie

JF - Pathologie Biologie

IS - 2

ER -

Update on tubulin-binding agents

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this